Menu
Recruiting NCT03795376

Dat'Aids Prevention

Observational HIV Prevention

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: HIV Prevention. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France, Guadeloupe, Martinique
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

HIV Prevention in France : "Dat'AIDS Prevention"

Overview

DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis

Primary outcome measures

  • Number of patients enrolled for HIV prevention in the cohort [Time frame: From date of enrollment, through study completion, an average of 1 year]
Secondary outcome measures (7)
  • Proportion of persons enrolled for pre-exposure prophylaxis in the cohort [Time frame: From date of enrollment, through study completion, an average of 1 year]
  • Proportion of persons enrolled for post-exposure prophylaxis in the cohort [Time frame: From date of enrollment, through study completion, an average of 1 year]
  • Proportion of persons enrolled for hepatitis screening in the cohort [Time frame: From date of enrollment, through study completion, an average of 1 year]
  • Proportion of persons enrolled for pre-exposure prophylaxis in the cohort according to national French guidelines [Time frame: From date of enrollment, through study completion, an average of 1 year]
  • Proportion of persons enrolled for post-exposure prophylaxis in the cohort according to national French guidelines [Time frame: From date of enrollment, through study completion, an average of 1 year]
  • Incidence of STIs [Time frame: From date of enrollment, through study completion, an average of 1 year]
  • Incidence of hepatitis [Time frame: From date of enrollment, through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

  • Male and female over 18 years old,
  • HIV negative
  • Attending for :
  • HIV screening
  • Hepatitis screening
  • STI screening / treatment
  • Blood, body fluid or sexual exposure
  • Post-exposure prophylaxis
  • Pre-exposure prophylaxis
  • Signed consent

Exclusion criteria

  • HIV-infection
  • Refusal to participate

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

France · 29 centers
  • Hôpital Nord Franche Comté — Belfort
  • CHU Besançon - Hôpital Jean Minjoz — Besançon
  • CHRU Brest — Brest
  • CHU Clermont-Ferrand - Hôpital Gabriel-Montpied — Clermont-Ferrand
  • CHD Vendée — La Roche-sur-Yon
  • Hôpital Bicêtre - Assistance Publique des Hôpitaux de Paris — Le Kremlin-Bicêtre
  • CHU Limoges — Limoges
  • Hôpital de la Croix-Rousse - Hospices Civils de Lyon — Lyon
  • … and 21 more centers
Guadeloupe · 1 center
  • CHU de Guadeloupe — Pointe-à-Pitre
Martinique · 1 center
  • CHU de Martinique — Fort-de-France

Identifiers

NCT: NCT03795376 · DAT_002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗